OncoTherapy Science, Inc. (JP:4564)
:4564
Want to see JP:4564 full AI Analyst Report?
Total Valuation
OncoTherapy Science has a market cap or net worth of ¥7.57B. The enterprise value is ¥5.97B.
Market Cap¥7.57B
Enterprise Value¥5.97B
Share Statistics
OncoTherapy Science has 398,643,700 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding398,643,700
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
OncoTherapy Science’s return on equity (ROE) is -0.43 and return on invested capital (ROIC) is -37.01%.
Return on Equity (ROE)-0.43
Return on Assets (ROA)-0.39
Return on Invested Capital (ROIC)-37.01%
Return on Capital Employed (ROCE)-0.37
Revenue Per Employee14.97M
Profits Per Employee-16.86M
Employee Count54
Asset Turnover0.34
Inventory Turnover12.73
Valuation Ratios
The current PE Ratio of OncoTherapy Science is ―. OncoTherapy Science’s PEG ratio is 0.67.
PE Ratio―
PS Ratio8.53
PB Ratio3.22
Price to Fair Value3.22
Price to FCF-7.00
Price to Operating Cash Flow―
PEG Ratio0.67
Income Statement
In the last 12 months, OncoTherapy Science had revenue of 808.53M and earned -910.64M in profits. Earnings per share was -2.77.
Revenue808.53M
Gross Profit13.96M
Operating Income-810.38M
Pretax Income-908.48M
Net Income-910.64M
EBITDA-810.38M
Earnings Per Share (EPS)-2.77
Cash Flow
In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.
Operating Cash Flow0.00
Free Cash Flow0.00
Free Cash Flow per Share0.00
Dividends & Yields
OncoTherapy Science pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.46
52-Week Price Change-13.64%
50-Day Moving Average22.74
200-Day Moving Average22.99
Relative Strength Index (RSI)35.45
Average Volume (3m)39.41M
Important Dates
OncoTherapy Science upcoming earnings date is Jan 29, 2027, TBA (Not Confirmed).
Last Earnings DateFeb 6, 2026
Next Earnings DateJan 29, 2027
Ex-Dividend Date―
Financial Position
OncoTherapy Science as a current ratio of 13.59, with Debt / Equity ratio of ―
Current Ratio13.59
Quick Ratio13.22
Debt to Market Cap0.00
Net Debt to EBITDA2.58
Interest Coverage Ratio-618.14
Taxes
In the past 12 months, OncoTherapy Science has paid 2.16M in taxes.
Income Tax2.16M
Effective Tax Rate>-0.01
Enterprise Valuation
OncoTherapy Science EV to EBITDA ratio is -5.93, with an EV/FCF ratio of -4.88.
EV to Sales5.94
EV to EBITDA-5.93
EV to Free Cash Flow-4.88
EV to Operating Cash Flow-5.21
Balance Sheet
OncoTherapy Science has ¥833.88M in cash and marketable securities with ¥37.14M in debt, giving a net cash position of ¥782.82M billion.
Cash & Marketable Securities¥833.88M
Total Debt¥37.14M
Net Cash¥782.82M
Net Cash Per Share¥1.96
Tangible Book Value Per Share¥6.53
Margins
Gross margin is ―, with operating margin of -100.23%, and net profit margin of -112.63%.
Gross Margin―
Operating Margin-100.23%
Pretax Margin-112.36%
Net Profit Margin-112.63%
EBITDA Margin-100.23%
EBIT Margin-100.23%
Analyst Forecast
The average price target for OncoTherapy Science is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast7.80%
EPS Growth Forecast12.92%